1. Academic Validation
  2. Pharmacological profile of neuroleptics at human monoamine transporters

Pharmacological profile of neuroleptics at human monoamine transporters

  • Eur J Pharmacol. 1999 Mar 5;368(2-3):277-83. doi: 10.1016/s0014-2999(99)00005-9.
M Tatsumi 1 K Jansen R D Blakely E Richelson
Affiliations

Affiliation

  • 1 Mayo Clinic Jacksonville, FL 32224, USA.
Abstract

Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the human serotonin, norepinephrine, and dopamine transporters with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively. Among neuroleptics, the four most potent compounds at the human Serotonin Transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM). At the human Dopamine Transporter, only pimozide (K(D) = 69+/-3) ziprasidone (K(D) = 76+/-5) had notable potency. These data may be useful in predicting therapeutic and adverse effects, including drug interactions of neuroleptics.

Figures
Products